Both tadalafil and sildenafil block PDE5 and improve endothelial function. But their pharmacokinetics, cardiovascular evidence base, and practical utility for longevity are meaningfully different. Here is how to think about the choice.
PDE5 inhibitors as a class have a strong cardiovascular and longevity rationale. The mechanism — blocking the enzyme that degrades cGMP and thereby sustaining nitric oxide signaling throughout the vascular system — applies equally to tadalafil and sildenafil.
But tadalafil and sildenafil are not interchangeable for longevity purposes. Their pharmacokinetics are fundamentally different, and that difference has direct implications for which compound makes more sense as a daily cardiovascular maintenance protocol.
This is the comparison that matters.
For endothelial function and cardiovascular protection, the mechanism requires continuous PDE5 inhibition — not an acute 4-hour window. Tadalafil's pharmacokinetics fit continuous endothelial maintenance; sildenafil's do not without multiple daily doses.
This is not a pharmacological opinion. It is reflected directly in how the drugs are licensed: tadalafil has a once-daily indication; sildenafil does not. The daily-dose tadalafil protocol studied in the clinical trials is a product of this pharmacological property.